Functional Analysis of BRCAness (FAB)
Correlation Between Homologous Recombination Deficiency and Response to Olaparib in Patients With Recurrent Epithelial Ovarian Cancer (EOC)
Sponsor: Erasmus Medical Center
Terminated
recruitment was lower than expected (28/55) due to registration of the IMP in the first and second line treatment
Other terminated trials from Erasmus Medical Center
Other BRCA1 Mutation trials with similar outcome
A PHASE2 clinical study on BRCA1 Mutation and BRCA2 Mutation, this trial is terminated or withdrawn. The trial is conducted by Erasmus Medical Center and has accumulated 6 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE2
Status: Unknown → Terminated
-
Sep 2024 — Feb 2026 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jul 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
May 2021 — Jul 2023 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE2
First recorded
Jan 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Erasmus Medical Center
- Leiden University Medical Center
- University Medical Center Groningen
For direct contact, visit the study record on ClinicalTrials.gov .